

## **JPMA's Public Comments on Section 232 National Security Investigation of**

### **Imports of Pharmaceuticals and Pharmaceutical Ingredients. 7th May, 2025**

- The pharmaceutical industry in Japan, together with the pharmaceutical industry in the United States, is making every effort to ensure the stable supply of pharmaceuticals that protect the health and lives of not only the Japanese people but also the American people, thereby contributing to the health security of the United States, and will continue to do so in the future.
- United States and Japan have a long history of not imposing tariffs on medicines from each other, and that these two countries should formalize zero tariffs on medicines through a bilateral sectoral agreement.
- Japanese pharmaceutical companies have made substantial investments in the United States, creating significant employment opportunities, and remain committed to expanding these investments.
- However, we must highlight several potential impacts if new tariff measures are implemented:
  - The pharmaceutical supply chain is globalized and complex, and relocating manufacturing sites requires significant time and expense, including compliance with U.S. pharmaceutical regulations. In particular, technology transfer for biopharmaceuticals requires considerable time and expense.
  - The imposition of tariffs on pharmaceuticals and pharmaceutical ingredients could lead to increased manufacturing costs and ultimately higher prices for U.S. consumers, potentially affecting access to innovative medicines.
  - There is concern that the interests of Japanese companies may be undermined, potentially leading to a reduction in investment in the United States.
- We remain committed to ensuring a stable supply of innovative medicines to United States patients and continuing proactive investment in the United States. Regarding tariff measures, we request that appropriate decisions be made to ensure that access to pharmaceuticals for both nations is not impaired.